Stacy Ku
Stock Analyst at TD Cowen
(4.36)
# 1,220
Out of 4,355 analysts
165
Total ratings
54.5%
Success rate
12.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLGL Sol-Gel Technologies | Initiated Coverage: Buy | n/a | $73.86 | - | 1 | May 29, 2026 | |
| TARA Protara Therapeutics | Rated: Buy | n/a | $4.65 | - | 14 | May 20, 2026 | |
| VRCA Verrica Pharmaceuticals | Maintained: Buy | $20 | $5.76 | +247.22% | 14 | May 12, 2026 | |
| TNXP Tonix Pharmaceuticals Holding | Maintained: Buy | $22 | $12.33 | +78.43% | 2 | May 11, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | $60 | $7.78 | +671.21% | 17 | May 11, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Buy | $17 | $15.33 | +10.89% | 13 | May 7, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintained: Buy | $30 | $8.91 | +236.70% | 16 | May 6, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $65 | $46.18 | +40.75% | 20 | May 5, 2026 | |
| GRCE Grace Therapeutics | Rated: Buy | $12 → $8 | $2.57 | +211.28% | 2 | Apr 23, 2026 | |
| KALV KalVista Pharmaceuticals | Maintained: Buy | $35 | $26.87 | +30.26% | 14 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €310.00 | $244.16 | +26.96% | 22 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $165 → $175 | $145.50 | +20.27% | 6 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $39.76 | - | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.6819 | +193.30% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $5.99 | - | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $15.95 | - | 3 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $19.18 | n/a | 1 | Feb 26, 2025 |
Sol-Gel Technologies
May 29, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $73.86
Upside: -
Protara Therapeutics
May 20, 2026
Rated: Buy
Price Target: n/a
Current: $4.65
Upside: -
Verrica Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $20
Current: $5.76
Upside: +247.22%
Tonix Pharmaceuticals Holding
May 11, 2026
Maintained: Buy
Price Target: $22
Current: $12.33
Upside: +78.43%
LENZ Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $60
Current: $7.78
Upside: +671.21%
Aurinia Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $17
Current: $15.33
Upside: +10.89%
BioCryst Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $30
Current: $8.91
Upside: +236.70%
Supernus Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $65
Current: $46.18
Upside: +40.75%
Grace Therapeutics
Apr 23, 2026
Rated: Buy
Price Target: $12 → $8
Current: $2.57
Upside: +211.28%
KalVista Pharmaceuticals
Mar 25, 2026
Maintained: Buy
Price Target: $35
Current: $26.87
Upside: +30.26%
Mar 19, 2026
Reiterated: Buy
Price Target: €310.00
Current: $244.16
Upside: +26.96%
Mar 13, 2026
Maintained: Buy
Price Target: $165 → $175
Current: $145.50
Upside: +20.27%
Nov 12, 2025
Maintained: Buy
Price Target: n/a
Current: $39.76
Upside: -
Nov 7, 2025
Maintained: Buy
Price Target: $2
Current: $0.6819
Upside: +193.30%
Oct 30, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $5.99
Upside: -
Oct 14, 2025
Maintained: Buy
Price Target: n/a
Current: $15.95
Upside: -
Feb 26, 2025
Maintained: Buy
Price Target: n/a
Current: $19.18
Upside: n/a